The results of the present study indicate that the addition of G to E plus T as front line treatment for advanced breast cancer is well tolerated with an ORR of 92%. On the basis of the high activity and interesting progression free and overall survival rates, the GET combination deserves further evaluation in randomized trials.

RESULTS.The median number of circulating CD34/ cells at peak was 70/mL; in 1 Division of Medical Oncology, University of the patients less heavily pretreated, it was 106.7/mL. The mean number of CD34/, Pisa, Pisa, Italy.CD34//CD330, and CD34//CD380 cells/kg collected per apheresis was 6.3 1 2 Institute of Pediatrics, University of Pisa, Pisa, 10 6 , 2.0 1 10 6 , and 0.18 1 10 6 , respectively. The mean number of CD34/ cells/kg Italy.per apheresis was 7.8 1 10 6 when the preleukapheresis CD34/ cell count was more than 50/mL and 0.9 1 10 6 when the CD34/ cell count was less than 50/mL. over, 15 -30% of the patients are progression free after 5 years.

The pharmacogenetic statistical interaction between VEGFR-2 rs11133360 and IL-8 rs4073 genotypes may identify a population of patients with a better outcome.

No abstract

High-dose thiotepa and melphalan after an epirubicin-paclitaxel-containing treatment is feasible, devoid of significant cardiotoxicity and very active. Pharmacokinetic parameters of high-dose thiotepa might be linked to treatment outcome.